BIRC2 and melanoma: Third, pharmacologic depletion of cIAP1/2 by birinapant, a bivalent second mitochondria-derived activator of caspases mimetic drug increased the efficiency of ICB in preclinical models of melanoma and glioblastoma (31, 33).